RESULTS FOR : 'Biologics'
Showing 1 to 11 of 11 results |    
Keyword Search
Show#
Show#
Results Category/Section
Just-Evotec Biologics to make monoclonal antibody products for COVID-19

The US Department of Defence (DOD) has awarded Evotec's Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19

Cobra Biologics delivers final plasmids for production of CG01 in epilepsy project

Cobra Biologics has produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.

Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

GSK and Samsung Biologics partner for additional manufacturing capacity

GlaxoSmithKline (GSK) and Samsung Biologics announced they have entered into a partnership to provide GSK with additional capacity to manufacture and supply its innovative biopharmaceutical therapies.

Boehringer Ingelheim acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline

The research-driven pharmaceutical company said the new acquisition provides assets targeting the tumour stroma and myeloid cells. Boehringer Ingelheim also announced it is collaborating with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, a leading cause of blindness.

Biologics Drug Discovery - Driving Strategic Improvements With Scientific Informatics

Adoption of a scientific informatics system is essential to the success of every drug discovery organisation. This article discusses how we can drive strategic improvements in biologics drug discovery using scientific informatics.

Raising The Bar On The Biologics Potential

In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.

The Chinese Biologics Drug Market: Demand and Execution

In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.

Balancing A Biologics Pipeline Portfolio

Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology.

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics

Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical utility and demonstrate attenuation in the disease progression of rheumatoid arthritis.